Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EBITDA (2016 - 2025)

Immucell (ICCC) has disclosed EBITDA for 16 consecutive years, with $20075.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 103.49% year-over-year to $20075.0, compared with a TTM value of $2.3 million through Sep 2025, up 2.37%, and an annual FY2024 reading of -$1.6 million, down 35.36% over the prior year.
  • EBITDA was $20075.0 for Q3 2025 at Immucell, down from $569562.0 in the prior quarter.
  • Across five years, EBITDA topped out at $4.5 million in Q4 2023 and bottomed at -$2.3 million in Q1 2023.
  • Average EBITDA over 5 years is -$114876.3, with a median of -$300052.0 recorded in 2024.
  • The sharpest move saw EBITDA tumbled 1223.53% in 2022, then soared 472.48% in 2025.
  • Year by year, EBITDA stood at $145412.0 in 2021, then crashed by 1223.53% to -$1.6 million in 2022, then surged by 377.67% to $4.5 million in 2023, then plummeted by 86.3% to $621395.0 in 2024, then plummeted by 96.77% to $20075.0 in 2025.
  • Business Quant data shows EBITDA for ICCC at $20075.0 in Q3 2025, $569562.0 in Q2 2025, and $1.1 million in Q1 2025.